ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)-Reference-Cited by-同舟云学术

ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Published:2021-07-06 Issue:5 Volume:128 Page:642-651
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Emmett Louise¹²³^ORCID,Subramaniam Shalini⁴^ORCID,Joshua Anthony M.⁵,Crumbaker Megan²³⁵,Martin Andrew⁴,Zhang Alison Y.⁴,Rana Nisha⁶,Langford Ailsa⁴,Mitchell Jenna⁴,Yip Sonia⁴,Francis Roslyn⁷,Hofman Michael S.⁸^ORCID,Sandhu Shahneen⁸,Azad Arun⁸^ORCID,Gedye Craig⁹,McJannett Margaret⁶,Stockler Martin R.⁴,Davis Ian D.¹⁰¹¹,

Affiliation:

1. Department of Theranostics and Nuclear Medicine St Vincent’s Hospital Sydney NSWAustralia

2. Garvan Institute of Medical Research Sydney NSWAustralia

3. University of New South Wales Sydney NSWAustralia

4. NHMRC Clinical Trials Centre University of Sydney Sydney NSWAustralia

5. Department of Medical Oncology Kinghorn Cancer Centre St Vincent’s Hospital Sydney NSWAustralia

6. Australian and New Zealand Urogenital and Prostate Cancer Trials Group Sydney NSWAustralia

7. Sir Charles Gairdner Hospital Perth WAAustralia

8. Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne VicAustralia

9. Calvary Mater Newcastle Waratah NSWAustralia

10. Eastern Health Clinical School Monash University Melbourne Vic.Australia

11. Eastern Health Melbourne Vic. Australia